Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HVA Regimen in the Treatment of Mixed-Phenotype Acute Leukemia (MPAL)
NCT07517510Phase 2Enrolling by invitation
- Sponsor
- Guangdong Second Provincial General Hospital
- Start
- Apr 2026
- Primary completion
- Dec 2026
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of homoharringtonine in mixed phenotype acute leukemia (MPAL), sponsored by Guangdong Second Provincial General Hospital. Started Apr 2026; status: enrolling by invitation.
02
Drugs
homoharringtonine
03
Conditions
mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NCT07517510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07517510.